Hos disse patienter bør der tages hensyn til tolerancen over for kombinationsbehandlingen og tilstedeværelsen af øvrige kliniske eller prognostiske faktorer såsom graden af fibrose, hvis der overvejes afvigelser fra standard 24 ugers behandlingsvarighed.
In these patients, tolerability to combination therapy and the presence of additional clinical or prognostic factors such as degree of fibrosis should be taken into account when considering deviations from standard 24 weeks treatment duration.